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Abstract  
Background: Community-clinical linkages have been promoted as a means to improve population health.  The community pharmacy is 
an ideal location for these partnerships to occur due to the expertise of the community pharmacist. While the need for these 
partnerships exists, there are limited data regarding community pharmacists’ current participation in such programs. 
Objective: The purpose of this analysis was to assess Ohio community pharmacists’ involvement and interest in community-clinical 
linkages.   
Methods: An electronic survey tool containing 26 questions was developed to assess Ohio community pharmacists’ participation in 
community-clinical linkages and interest to develop such partnerships. The tool was sent via email to a random sample of 500 
pharmacists registered in Ohio and practicing in a community setting.  Chi-square or Fisher exact nonparametric statistical tests were 
used as appropriate to identify whether there were any significant differences in current partnership or interest to partner with a 
prescriber who refers patients to their community pharmacy based on education (Bachelor of Science or Doctor of Pharmacy degree) 
or pharmacy location (urban, suburban, or rural).   
Results: Nine emails were undeliverable, leaving a sample of 491 pharmacists.  Ninety-three (19%) responded to the survey.  Sixteen 
respondents (17%) indicated that they currently partner with a prescriber who refers patients to their pharmacy for assistance with 
medications or chronic disease state management; this practice was more often reported in urban settings (p=0.022).  Of those not 
currently participating in such a partnership, 53 (57%) were interested in developing one.  Thirty-two respondents (34%) reported 
providing referrals for at least 1 type of screening or counseling service.  For some types of services, pharmacists reported that they 
provide the service in the pharmacy and/or were interested to develop the service in the pharmacy rather than provide a referral.  
However, for any given service there were a number of pharmacists who expressed interest in providing referrals although they were 
not currently doing so. 
Conclusion: This sample of Ohio community pharmacists reported limited participation in community-clinical linkages but interest to 
develop them.  Further studies should explore the pharmacists’ role and impact in such programs. 
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Introduction 
Community-clinical linkages are connections between the 
community, clinics, and other primary care settings that help to 
ensure that those at high risk for chronic diseases and 
subsequent complications have access in the community to 
quality resources to best prevent, delay, or manage their 
conditions.  Access, referral, and payment for services may be 
facilitated through community-clinical linkages, thereby 
improving patient outcomes and population health.1-5   
 
Community pharmacies can be an integral part of community-
clinical linkages (Figure 1).  For example, recent reports by the 
Centers for Disease Control and Prevention (CDC) provide a 
blueprint for integrating community pharmacists into 
community-clinical linkages with public health and clinical 
sectors. The CDC indicates multiple ways in which community  
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pharmacists and physicians in primary care offices and hospitals 
can interface in community-clinical linkages to increase access 
to quality care, including (1) health assessment in the 
community pharmacy with referral (as needed) to a physician 
for diagnosis or treatment and (2) physician referral of patients 
to the community pharmacist for assistance with medications 
or chronic disease state management.2-4 
 
Currently, there is great need in the United States (U.S.) for 
community-clinical linkages to be formed. 1-5   For example, a 
recent article in Health Affairs showed that only 8% of adults in 
the U.S. 35 years and older had received all of recommended 
clinical preventive services in 2015.6 There are also ample 
opportunities for such partnerships to be formed,  given that 
the average American lives within 5 miles of a community 
pharmacy.7 However, there are limited data regarding 
community pharmacist participation in community-clinical 
linkages or interest in establishing such programs.  Therefore, 
the purpose of this analysis was to assess Ohio community 
pharmacists’ involvement and interest in community-clinical 
linkages with the clinical sector.   
 
 Methods 
A survey tool was developed to assess Ohio community 
pharmacists’ provision of clinical preventive services as well as 
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participation and interest in community-clinical linkages.  The 
tool utilized selected clinical preventive services8 
recommended by the U.S. Preventive Services Task Force as a 
framework. The tool contained 26 questions with 13 
demographic questions, 6 questions assessing pharmacists’ 
practices, and 7 questions soliciting opinions pharmacists held 
on these services.  
 
The tool was entered into Qualtrics Labs (Provo, UT) for 
distribution via e-mail.  Six pharmacists who had backgrounds 
in community pharmacy pilot-tested the survey before 
distribution. The objectives of the pilot-testing were twofold: 
(1) to check the face validity of the questions and (2) to test for 
any technical difficulties in the survey.  
 
Following completion of pilot testing, the survey was sent 
electronically to a sample of 500 randomly-selected 
pharmacists registered with the Ohio State Board of Pharmacy 
and currently practicing in a community pharmacy in Ohio.  As 
there may be a lack of familiarity among pharmacists regarding 
the term “community-clinical linkages”, the survey cover letter 
did not explicitly state the focus of the survey questions but 
rather indicated that the survey focused on “community 
pharmacy services.”   
 
Reminder emails were sent every 3-4 days, and the survey was 
closed after one month. No incentives were given for survey 
completion.  Surveys were completed anonymously.  The Ohio 
Northern University Institutional Review Board approved the 
study. 
 
Microsoft Office Excel 2013 (Redmond, WA) was used for 
descriptive statistics, and IBM SPSS 22 (Armonk, 
NY)/Vassarstats (Poughkeepsie, NY) were used for analytic 
statistics. Chi-square or Fisher exact nonparametric statistical 
tests were used as appropriate to identify whether there were 
any significant differences in current partnership or interest to 
partner with a prescriber who refers patients to their 
community pharmacy based on education (Bachelor of Science 
or Doctor of Pharmacy degree) or pharmacy location (urban, 
suburban, or rural).  Statistical significance was defined a priori 
as a p-value of < 0.05. 
 
Results 
Ninety-three community pharmacists responded to the survey 
(Table 1). Since 9 emails were undeliverable, this gave a 
response rate of 19%.  Detailed information regarding 
respondents’ direct provision of clinical preventive services that 
can be provided in a community pharmacy has already been 
reported.9 
 
In regards to community-clinical linkages, 16 (17%) of 
respondents indicated that they currently partner with a 
prescriber who refers patients to their community pharmacy 
for assistance with medications or chronic disease state 
management. Community pharmacists at urban locations 
reported such relationships more often than those at suburban 
or rural locations (p=0.022); there was no significant difference 
seen by education (p=0.316).  Fifty-three (57%) of those who 
are not currently participating in such a partnership reported 
being interested to develop one; no significant differences were 
seen based on education (p=0.542) or pharmacy location 
(p=0.231).   
 
Another aspect of community-clinical linkages are referrals by 
the community pharmacist to the clinical sector.  Thirty-two 
respondents (34%) reported providing referrals for at least 1 
type of service. There are a number of recommended 
counseling and screening services that could potentially be 
provided in the community pharmacy (Figure 2).  Between 4% 
to 9% of respondents indicated that they currently provide 
referrals for these types of services.  Respondents reported a 
greater interest in developing the service to be delivered in 
their own pharmacy, rather than developing a referral process 
to another source, for each of the 9 counseling services (Table 
2) and 7 of the 12 screening services (Table 3) assessed.  
However, there were 5 screening services for which slightly 
more respondents indicated an interest in providing a referral 
than in developing the service themselves: depression, 
hepatitis C, HIV, intimate partner violence, and tuberculosis 
(Table 3).  Additionally, community pharmacist interest and 
participation in referrals for screening services that are not 
typically feasible to be offered in community pharmacies 
(Figure 2) was assessed.   Between 2% to 4% of respondents 
reported currently providing referrals for these types of 
services, with approximately 24% of respondents indicating an 
interest to provide referrals although not currently doing so 
(Table 4).   
 
Discussion 
There are many potential roles for community pharmacists 
participating in community-clinical linkages with the clinical 
sector, including triaging of patients to the most appropriate 
source of care, referring patients to physicians or prescribers, 
and collaborating with prescribers to manage patients’ 
medications and chronic conditions.2-4 Community pharmacists 
can help fill the gap in provision of clinical preventive services, 
either through directly providing the service themselves if 
feasible or by referring patients to other sources to receive 
necessary care.10  These types of partnerships can result in 
increased access to care and improved patient outcomes.2-4 
Overall, respondents to this survey indicated low involvement 
in community-clinical linkages with the clinical sector but 
interest to develop them.   
 
While only 17% of community pharmacists reported 
partnerships with a prescriber who refers patients to their 
pharmacy for disease state management or medication 
management, 57% reported interest to develop such 
partnerships.  Resources such as those published by the CDC 
that are specific to community pharmacies and physicians may 
be helpful to those wanting to form such partnerships.2-3  
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Currently, those types of partnerships were more often 
reported among community pharmacists working in urban 
areas; there is a need to develop these partnerships especially 
in rural areas where the population tends to have higher rates 
of chronic disease, poorer overall health status, and fewer 
physician resources as compared to those living in urban 
areas.11,12  A clear and strong partnership should be developed 
so as to ensure a high rate of prescriber acceptance of 
pharmacist recommendations.2,3,13,15  
 
Interestingly, for some types of services more community 
pharmacists reported wanting to develop them rather than 
refer patients to another source.  Often-reported barriers to 
pharmacists creating new clinical services in the community 
pharmacy setting in the U.S. are time, space, and lack of staffing 
and reimbursement.15 These barriers need to be addressed so 
that pharmacists can provide comprehensive clinical preventive 
services to their patients.  A potential area for future research 
is to more fully explore what factors influence pharmacist 
interest in developing the service in the pharmacy rather than 
develop partnerships to refer patients to established providers.   
 
Regardless, there is an opportunity to educate community 
pharmacists regarding the important role they play in 
community-clinical linkages and to encourage them to refer 
patients as appropriate to the clinical sector.  There are some 
services that cannot fully be provided in the community 
pharmacy setting; for example, while there are reports of 
community pharmacist involvement in early detection activities 
for certain cancers, referrals for tests such as mammograms or 
colonoscopies will be required.16,17  Similarly, while there is 
potential for community pharmacists to provide screenings for 
sexually transmitted infections such as chlamydia and 
gonorrhea in the pharmacy,18 the practice is not currently 
widespread in the U.S. outside of sale of over-the-counter 
testing kits.  The number of respondents currently providing 
referrals for these types of screenings was quite low, but about 
24% of respondents were interested to create them.  
Community pharmacists should be encouraged to develop such 
referral services by reaching out to potential partners in the 
area to understand the varied services available to their 
patients. 
 
In addition, for some types of services (e.g., tobacco use 
counseling, screening for tobacco use, blood pressure 
screening) a sizeable number of pharmacists reported currently 
providing those services in the community pharmacy, which 
would naturally limit interest in developing referrals for these 
services.  However, there are many related aspects that should 
be explored in future research.  For example, previous reviews 
have determined low uptake of patients following through with 
the referrals to other healthcare providers provided by 
community pharmacists;15,19,20 therefore, even though blood 
pressure or tobacco use screenings are being performed in the 
community pharmacy, what process should be developed to 
ensure patients take their screening results to a prescriber for 
follow-up? What processes can be developed to avoid silos and 
to better integrate community pharmacies in the U.S. into a 
health information exchange, facilitating information exchange 
between community pharmacies and clinical and public health 
sectors?21 Pharmacists participating in community-clinical 
linkages may utilize novel practice models such as collaborative 
practice agreements and/or medication therapy management.2 
These types of practice models and the impact on patient 
receipt of clinical preventive services and appropriate 
treatment should be more fully studied. 
 
Furthermore, this survey only focused on linkages between 
community pharmacies and the clinical sector.  There are 
opportunities for community pharmacies to participate in 
community-clinical linkages with public health and community-
based organizations.4,22 For example, a recent toolkit developed 
by the National WIC Association (the non-profit education 
component of the Special Supplemental Nutrition Program for 
Women, Infants and Children [WIC]) highlighted community 
pharmacies as a potential partner in community-clinical 
linkages.23  Additional research to describe pharmacist 
participation in and best practices for such partnerships is 
warranted. 
 
Limitations to this study include response rate and possible 
response bias; therefore, results may not be generalizable to all 
community pharmacists practicing in Ohio.  Additionally, as 
pharmacist scope-of-practice varies by state and country, 
results may not be applicable to community pharmacists 
practicing in different parts of the U.S. or other nations.  As this 
was a preliminary study, there were no available data from 
which to draw sample size calculations. As a result, the analysis 
of the survey data is subject to type 2 error.  
 
Conclusion 
Community-clinical linkages have been promoted as a means to 
improve population health. Community pharmacists can play 
an important role in filling gaps in preventive services by 
increasing patient access to care by either providing a service in 
the pharmacy or referring patients to partners in the clinical 
sector.  Additionally, prescribers can refer patients to the 
pharmacy to manage their disease states and medications.  This 
analysis provided preliminary information on community 
pharmacists involvement in these types of community-clinical 
linkages. This sample of Ohio community pharmacists reported 
limited participation in community-clinical linkages but interest 
to develop them.  Further studies should explore the 
pharmacists’ role and impact in such programs. 
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Figure 1. Examples of linkages between the community and clinical sector3 
 
 
 
 
 
 
 
Figure 2.  Selected counseling and screening services recommended by the  
U.S. Preventive Services Task Force for the general, adult population6 
 
 
 
Community Sector
- Employer
- Faith-based organization
- Barbershop
- Community organization
- Nonprofit organization
- Community pharmacy
Clinical Sector
- Hospital
- Clinic
- Medical practice
- Federally-qualified 
health center
- Health system
Can be provided in community pharmacies
Counseling services: Alcohol misuse; Birth defect 
prevention (folic acid); Breastfeeding; Diet; Fall 
prevention; Physical activity; Skin cancer 
prevention; Sexually transmitted infection 
prevention; Tobacco use  
Screening services: Alcohol misuse; Blood 
pressure; Cholesterol; Depression; Hepatitis C; 
HIV; Intimate partner violence; Obesity; 
Osteoporosis; Tobacco use; Type 2 diabetes; 
Tuberculosis
Cannot be fully provided in community pharmacies
Screening services: Abdominal aortic aneurysm; 
BRCA risk assessment and testing; Breast cancer; 
Cervical cancer; Colorectal cancer; Lung cancer; 
Sexually trnasmitted infections (i.e., chlamydia, 
gonorrhea, syphilis)
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Table 1. Characteristics of survey respondents (n=93) 
 
Characteristic n (%) 
Gender 
      Male 
      Female 
      Prefer not to answer 
 
33 (35) 
59 (64) 
  1 (1) 
Education* 
      Bachelor of Science in Pharmacy 
      Doctor of Pharmacy 
      Residency 
 
50 (54) 
48 (52) 
  2 (2) 
Years in Practice 
       5 years or less 
       6-10 years 
      11-20 years 
      More than 20 years 
 
25 (27) 
19 (20) 
13 (14) 
36 (39) 
Position* 
      Staff pharmacist 
      Pharmacy manager 
      Clinical/MTM pharmacist 
 
52 (56) 
42 (45) 
11 (12) 
Employment status 
      Full-time 
      Part-time 
 
82 (88) 
11 (12) 
Location 
      Rural 
      Suburban 
      Urban 
 
23 (25) 
44 (47) 
26 (28) 
Practice Setting 
      Chain pharmacy (e.g., CVS, Walgreens, etc) 
      Grocery (e.g., Kroger, Giant Eagle, etc) 
      Mass merchandiser (ex: Walmart, Kmart, etc) 
      Independent pharmacy  
      Blank 
 
39 (42) 
26 (28) 
10 (11) 
16 (17) 
  2 (2) 
* Respondents could select >1 choice 
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Table 2. Ohio community pharmacist (n=93) responses regarding counseling services 
Service Currently 
provide 
referral      
n (%) 
Interested 
in providing 
referral        
n (%) 
Currently 
provide in 
pharmacy                  
n (%)7 
Interested     
in providing 
in pharmacy                    
n (%)7 
Not interested   
in providing or 
referring 
n (%) 
Blank 
N (%) 
Alcohol misuse 6 (7%) 26 (28%) 4 (4%) 33 (35%) 24 (26%) 0  
Birth defect 
prevention – folic acid 
4 (4%) 20 (22%) 19 (20%) 34 (37%) 15 (16%) 1 (1%) 
Breastfeeding 8 (9%) 27 (29%) 1 (1%) 30 (32%) 27 (29%) 0 
Diet 14 (15%) 20 (22%) 16 (17%) 30 (32%) 13 (14%) 0 
Fall prevention  6 (6%) 21 (23%) 13 (14%) 39 (42%) 14 (15%) 0 
Physical activity 9 (10%) 24 (26%) 12 (13%) 30 (32%) 18 (19%) 0 
Skin cancer prevention 8 (9%) 25 (27%) 9 (10%) 36 (39%) 15 (16%) 0 
Sexually transmitted 
infection prevention 
6 (6%) 22 (24%) 5 (5%) 31 (33%) 29 (31%) 0 
Tobacco use 3 (3%) 13 (14%) 38 (41%) 27 (29%) 12 (13%) 0 
* percentages may not total 100 due to rounding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Original Research PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                         2019, Vol. 10, No. 2, Article 18                     INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v10i2.1760 
8 
 
 
 
 
 
 
Table 3.  Ohio community pharmacist (n=93) responses regarding  
screening services that can be provided in community pharmacies 
Service Currently 
provide 
referral                
n (%) 
Interested in 
providing 
referral           
n (%) 
Currently 
provide in 
pharmacy                  
n (%)7 
Interested           
in providing in 
pharmacy                    
n (%)7 
Not interested   
in providing or 
referring 
n (%) 
Blank 
n(%) 
Alcohol misuse 6 (6%) 26 (28%) 2 (2%) 33 (35%) 24 (26%) 2 (2%) 
Blood pressure 6 (6%) 7 (8%) 48 (52%) 22 (24%) 9 (10%) 1 (1%) 
Cholesterol 8 (9%) 13 (14%) 16 (17%) 40 (43%) 15 (16%) 1 (1%) 
Depression 6 (6%) 29 (31%) 2 (2%) 27 (29%) 27 (29%) 2 (2%) 
Hepatitis C 4 (4%) 32 (34%) 2 (2%) 27 (29%) 26 (28%) 2 (2%) 
HIV 6 (6%) 31 (33%) 2 (2%) 24 (26%) 29 (31%) 1 (1%) 
Intimate partner violence 4 (4%) 28 (30%) 0 22 (24%) 38 (41%) 1 (1%) 
Obesity 7 (8%) 22 (24%) 7 (8%) 34 (37%) 22 (24%) 1 (1%) 
Osteoporosis 5 (5%) 24 (26%) 0 41 (44%) 22 (24%) 1 (1%) 
Tobacco use 4 (4%) 17 (18%) 22 (24%) 29 (31%) 20 (22%) 1 (1%) 
Type 2 diabetes 7 (8%) 13 (14%) 19 (20%) 39 (42%) 14 (15%) 1 (1%) 
Tuberculosis 8 (9%) 27 (29%) 0 26 (28%) 31 (33%) 1 (1%) 
* percentages may not total 100 due to rounding 
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Table 4.  Ohio community pharmacist (n=93) responses regarding  
screening services that cannot be fully provided in community pharmacies 
Service Currently 
providing 
education 
n (%) 
Interested 
in providing 
education 
n (%) 
Currently 
provide 
referral                
n (%) 
Interested in 
providing 
referral            
n (%) 
Not interested 
in providing 
education or 
referrals 
n (%) 
Blank 
n(%) 
Abdominal aortic aneurysm 
screening 
2 (2%) 14 (15%) 3 (3%) 23 (25%) 44 (47%) 7 (8%) 
BRCA risk assessment and testing 0 21 (23%) 3 (3%) 21 (23%) 3 (3%) 5 (5%) 
Breast cancer screening 1 (1%) 23 (25%) 2 (2%) 21 (23%) 41 (44%) 5 (5%) 
Cervical cancer screening 1 (1%) 21 (23%) 3 (3%) 23 (25%) 40 (43%) 5 (5%) 
Colorectal cancer screening 2 (2%) 22 (24%) 2 (2%) 24 (26%) 38 (41%) 5 (5%) 
Lung cancer screening 0 23 (25%) 3 (3%) 23 (25%) 38 (41%) 5 (5%) 
Sexually transmitted infection 
screening (i.e., chlamydia, 
gonorrhea, syphilis) 
2 (2%) 20 (22%) 4 (4%) 21 (23%) 41 (44%) 5 (5%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
